Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 122,518 | 225,467 | 74,940 | 73,680 | 94,857 |
| Marketable Securities | 759,703 | 737,068 | 783,195 | 864,538 | 981,157 |
| Receivables | 17,764 | 1,808 | 8,410 | 2,012 | 16,650 |
| TOTAL | $916,975 | $977,349 | $886,542 | $956,053 | $1,107,940 |
| Non-Current Assets | |||||
| PPE Net | 79,194 | 76,001 | 70,219 | 67,175 | 65,815 |
| Investments And Advances | 335,048 | 288,817 | 178,201 | 150,687 | 145,055 |
| Other Non-Current Assets | 93,320 | 94,390 | 90,673 | 90,136 | 82,863 |
| TOTAL | $507,562 | $459,208 | $339,093 | $307,998 | $293,733 |
| Total Assets | $1,424,537 | $1,436,557 | $1,225,635 | $1,264,051 | $1,401,673 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 41,181 | 37,927 | 14,400 | 12,960 | 11,520 |
| Accounts payable and accrued liabilities | 22,337 | 22,084 | 16,228 | 13,942 | 20,369 |
| Accrued Expenses | 83,278 | 61,633 | 52,315 | 43,358 | 55,323 |
| Other current liabilities | 34,933 | 18,888 | 27,192 | 17,522 | 21,114 |
| TOTAL | $202,452 | $142,144 | $131,064 | $159,726 | $179,674 |
| Non-Current Liabilities | |||||
| Long Term Debt | 246,384 | 158,747 | 159,058 | 92,025 | 93,227 |
| Deferred Revenues | 1,612 | 1,612 | 1,344 | 52,370 | 52,370 |
| Other Non-Current Liabilities | 1,635,326 | 1,656,789 | 1,304,233 | 1,278,713 | 1,264,144 |
| TOTAL | $1,881,710 | $1,815,536 | $1,463,291 | $1,370,738 | $1,357,371 |
| Total Liabilities | $2,084,162 | $1,957,680 | $1,594,355 | $1,530,464 | $1,537,045 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 123,163 | 122,265 | 119,657 | 119,427 | 118,411 |
| Common Shares | 123 | 122 | 119 | 119 | 118 |
| Retained earnings | -3,486,719 | -3,303,688 | -2,997,510 | -2,863,140 | -2,701,764 |
| Other shareholders' equity | 630 | 34 | -158 | 1,545 | 2,398 |
| TOTAL | $-659,625 | $-521,123 | $-368,720 | $-266,413 | $-135,372 |
| Total Liabilities And Equity | $1,424,537 | $1,436,557 | $1,225,635 | $1,264,051 | $1,401,673 |